Immunohistochemistry of 166 HCC surgical specimens showed that compared to SOX9− patients, SOX9+ patients had significantly poorer recurrence-free survival, stronger venous invasion (Kawai et al., 2016). This evidence concerns the gene SOX9 and hepatocellular carcinoma.